Outlook
CAGR
- Global: 40%
- US: 27.1% (2026–2031)
- India: not yet sized independently; largely outsourced-services model (e.g. Infinx, AGS Health serving US health systems)
Market size
- Global: 2025: $25.88B · 2026: $36.67B · 2031: $194.79B
- US: 2026: $21.49B → 2031: $71.27B
- India: not yet sized independently
Note on figures: the global (40% CAGR, $194.79B by 2031) and US-specific (27.1% CAGR, $71.27B by 2031) series come from different research sources and likely use different market definitions — the global figure may capture a broader “AI in healthcare administration” scope while the US figure is narrower (“AI in RCM” specifically). Both are shown as reported; source attribution for the global figure to be added once confirmed.
AI maturity
High. RCM is the most PE-mature segment of AI in healthcare — proven ROI, real revenue at scale, multiple completed take-private and recapitalization transactions.
Key players
- Waystar — hybrid subscription + volume-based RCM platform; ~30,000 clients, ~1M providers; NRR 109.7% (TTM June 2023); IPO’d June 2024 (EQT-backed)
- R1 RCM — end-to-end revenue cycle outsourcing + autonomous coding AI; ~$2.1B revenue; taken private by TowerBrook and CD&R in an $8.9B deal (Nov 2024)
- Cotiviti — payment accuracy and data analytics for payers; $11B recapitalization co-sponsored by Veritas Capital and KKR
- Optum (UnitedHealth) — integrated payer-provider RCM at scale
- Infinx — India-based AI-driven RCM serving the US market; KKR-backed minority stake
PE attractiveness
Very high. ROI is directly measurable in dollars saved (denial reduction, days-in-AR improvement, cost-to-collect reduction) rather than softer clinical-outcome metrics. Deep EHR integration creates genuine switching costs. This is the segment with the most completed PE transactions to date.
PE firms present, stakes, and strategic vision
- TowerBrook Capital Partners + Clayton, Dubilier & Rice — acquired R1 RCM in an $8.9B take-private (Nov 2024), the largest sponsor-driven health-tech public-to-private deal on record. Post-close, partnered with Palantir on an AI initiative targeting coding, billing, and denial management — the strategic vision is an autonomous revenue cycle with minimal human touch on routine claims.
- Veritas Capital + KKR — co-sponsored an $11B recapitalization of Cotiviti, doubling down on payer-side data analytics and payment accuracy.
- KKR — separately holds a significant minority stake in Infinx, extending the RCM thesis into an India-based delivery model serving US health systems.
- EQT — built Waystar from the 2017 Navicure/ZirMed merger through 8 acquisitions (2018–2023) into a platform IPO’d in June 2024; used IPO proceeds to retire the more expensive second-lien debt tranche first, a classic delever-before-exit move.
Data still to source
- GRR (gross revenue retention) is not publicly disclosed by any major player in this segment, including Waystar — flagged as a standing diligence gap, not evidence of high or low churn either way.
- India-specific market sizing and CAGR.
- Global (ex-US) market sizing, reconciled to a single source.